InnoCare Pharma Ltd. (HK:9969)
:9969
Want to see HK:9969 full AI Analyst Report?
Top Page
InnoCare Pharma Ltd.
(9969)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$15.50
▲(31.91% Upside)
Action:ReiteratedDate:04/25/26
The score is primarily driven by a strong profitability turnaround and manageable leverage, offset by weaker and more volatile cash generation versus 2025. Technical indicators are mildly supportive, while valuation (P/E ~31) is a headwind.
Positive Factors
Profitability turnaround
Very high gross margin (~91%) and strong EBIT/net margins indicate durable unit economics and operational leverage. Sustained margins provide long-term capacity to fund R&D and commercialization, underpinning profitability even if top-line growth moderates.
Negative Factors
Weaker, volatile cash generation
Cash generation has weakened sharply versus the prior year, with OCF and FCF down materially. Profitability has not consistently converted to cash, reducing internal funding for R&D/commercial needs and increasing reliance on external financing over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability turnaround
Very high gross margin (~91%) and strong EBIT/net margins indicate durable unit economics and operational leverage. Sustained margins provide long-term capacity to fund R&D and commercialization, underpinning profitability even if top-line growth moderates.
Read all positive factors
InnoCare Pharma Ltd. (9969) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$21.97B
Dividend YieldN/A
Average Volume (3M)17.45M
Price to Earnings (P/E)50.1
Beta (1Y)1.03
Revenue Growth110.05%
EPS GrowthN/A
CountryHK
Employees1,089
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,496,284,200
10 Day Avg. Volume19,701,315
30 Day Avg. Volume17,452,168
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.52
Price to Sales (P/S)8.47
P/FCF Ratio148.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.86Price Target Upside68.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InnoCare Pharma Ltd. Business Overview & Revenue Model
Company Description
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed an...
How the Company Makes Money
null...
InnoCare Pharma Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.50B | 2.30B | 1.01B | 738.54M | 625.40M | 1.04B |
| Gross Profit | 2.26B | 2.01B | 871.01M | 610.10M | 482.01M | 977.37M |
| EBITDA | 645.06M | 555.89M | -463.49M | -516.55M | -808.28M | 16.23M |
| Net Income | 719.26M | 625.84M | -440.63M | -631.26M | -886.59M | -64.55M |
Balance Sheet | ||||||
| Total Assets | 10.35B | 10.83B | 9.41B | 9.92B | 10.32B | 7.40B |
| Cash, Cash Equivalents and Short-Term Investments | 7.07B | 7.34B | 6.22B | 8.22B | 9.01B | 6.25B |
| Total Debt | 1.80B | 1.61B | 1.27B | 1.35B | 1.25B | 1.27B |
| Total Liabilities | 3.01B | 2.79B | 2.66B | 2.74B | 2.68B | 1.74B |
| Stockholders Equity | 7.32B | 7.73B | 6.73B | 7.15B | 7.60B | 5.60B |
Cash Flow | ||||||
| Free Cash Flow | 29.97M | 130.80M | -443.78M | -926.00M | -935.88M | -11.00K |
| Operating Cash Flow | 105.04M | 199.15M | -365.55M | -671.34M | -565.55M | 167.06M |
| Investing Cash Flow | -905.78M | -358.03M | 1.11B | 666.91M | -1.73B | -1.73B |
| Financing Cash Flow | 118.57M | -32.84M | -285.60M | 1.31M | 3.09B | 2.54B |
InnoCare Pharma Ltd. Technical Analysis
Positive
11.75
Price Trends
12.80
Positive
13.07
Positive
14.77
Positive
Market Momentum
0.90
Negative
71.56
Negative
84.73
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9969, the sentiment is Positive. The current price of 11.75 is below the 20-day moving average (MA) of 13.96, below the 50-day MA of 12.80, and below the 200-day MA of 14.77, indicating a bullish trend. The MACD of 0.90 indicates Negative momentum. The RSI at 71.56 is Negative, neither overbought nor oversold. The STOCH value of 84.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9969.
InnoCare Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$44.97B | 34.57 | 25.67% | ― | 16.65% | 0.87% | |
63 Neutral | HK$21.97B | 50.10 | 9.08% | ― | 110.05% | ― | |
58 Neutral | HK$14.28B | -86.94 | -11.81% | ― | 219.26% | 87.63% | |
53 Neutral | HK$13.08B | -38.53 | -11.43% | ― | 142.64% | 72.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$17.33B | -13.81 | -123.74% | ― | -41.32% | -159.81% | |
41 Neutral | HK$21.34B | -25.84 | -17.26% | ― | 66.66% | 7.19% |
* Healthcare Sector Average
HK:9969
InnoCare Pharma Ltd.
13.87
4.15
42.70%
HK:1952
Everest Medicines Ltd.
35.38
-9.22
-20.67%
HK:2162
Keymed Biosciences, Inc.
75.65
32.40
74.91%
HK:2171
CARsgen Therapeutics Holdings Ltd.
24.18
8.92
58.45%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
79.90
42.05
111.10%
HK:6855
Ascentage Pharma Group International
46.12
-3.23
-6.55%
InnoCare Pharma Ltd. Corporate Events
InnoCare Pharma Sets 2026 AGM to Approve 2025 Results and Renew Share Issuance Mandate
Apr 24, 2026
InnoCare Pharma has called its annual general meeting for 16 June 2026 in Beijing, where shareholders will review the company’s audited consolidated financial statements and related reports for the year ended 31 December 2025. The agenda als...
InnoCare Pharma Grants RSUs Tied to Revenue and R&D Milestones
Apr 24, 2026
InnoCare Pharma has granted 15,389,245 restricted share units under its 2023 Share Award Scheme to three grantees, including executive directors Dr. Cui and Dr. Zhao and a senior manager, representing about 0.87% of its issued share capital. The R...
InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver
Apr 24, 2026
InnoCare Pharma plans to adopt a new 2026 RMB Share Incentive Scheme at its upcoming annual general meeting to strengthen its long-term incentive mechanisms and tie employees’ interests more closely to those of shareholders. The scheme aims ...
InnoCare Pharma Issues Unaudited PRC-GAAP Q1 2026 Report for STAR Market Compliance
Apr 23, 2026
InnoCare Pharma Limited has released its unaudited 2026 first-quarter report, prepared under PRC accounting standards for compliance with the STAR Market of the Shanghai Stock Exchange. The report, translated from the Chinese original, has been re...
InnoCare Pharma Sets April Board Meeting to Approve Q1 2026 Results
Apr 10, 2026
InnoCare Pharma has scheduled a board meeting for 23 April 2026 to review and approve its unaudited first-quarter results for the period ended 31 March 2026. The move signals that the company is preparing to publish its latest financial performanc...
InnoCare Pharma Moves to Modernize Governance With New Corporate Charter
Mar 25, 2026
InnoCare Pharma has proposed amendments to its existing memorandum and articles of association to align its corporate constitution with recent changes to Hong Kong listing regulations. The revisions would permit the cancellation or holding of repu...
InnoCare Tightens Audit Committee Rules to Bolster Governance
Mar 25, 2026
InnoCare Pharma Limited has formalized the terms of reference for its audit committee, a governance body first established by the board in September 2019, to align with Hong Kong Listing Rules and the applicable rules of the STAR Market. The docum...
InnoCare Pharma Tightens Governance With Formal Compensation Committee Mandate
Mar 25, 2026
InnoCare Pharma’s board has formalized detailed terms of reference for its Compensation Committee, originally established in 2019, to strengthen governance over remuneration. The document defines key roles, including senior management, and c...
InnoCare Pharma Updates Nomination Committee Governance Framework
Mar 25, 2026
InnoCare Pharma Limited has formalized and disclosed the terms of reference for its Nomination Committee, which was originally established by its board in September 2019. The committee must comprise at least three directors, with a majority being ...
InnoCare Pharma Swings to Profit on Surging Drug Sales and Licensing Revenue
Mar 25, 2026
InnoCare Pharma Limited, a biopharmaceutical company specializing in innovative oncology and autoimmune therapies, reported a strong jump in revenue and a return to profitability in 2025. The group’s growth is driven by sales of its flagship...
InnoCare Pharma Adjusts Internal Allocation of STAR Market Share Proceeds
Mar 25, 2026
InnoCare Pharma Limited, a biopharmaceutical group incorporated in the Cayman Islands and listed in Hong Kong and on Shanghai’s STAR Market, focuses on innovative drug development and commercialization in China’s healthcare sector. The...
InnoCare Pharma Updates Company Secretary and Governance Roles
Mar 25, 2026
InnoCare Pharma Limited announced a leadership change in its corporate governance functions, with company secretary and authorized representative Ms. Lee Angel Pui Shan resigning effective 25 March 2026, while confirming she has no disagreement wi...
InnoCare Pharma Sets March 2026 Board Meeting to Approve 2025 Annual Results
Mar 12, 2026
InnoCare Pharma has scheduled a board meeting for 25 March 2026 to review and approve the annual results for the year ended 31 December 2025. The approval will pave the way for publication of the company’s full-year financial performance, a ...
InnoCare Pharma Forecasts First Annual Profit in 2025 on Surging Drug Sales
Jan 29, 2026
InnoCare Pharma said it expects a sharp improvement in its 2025 financial performance, projecting operating revenue of about RMB2.37 billion, up roughly 134% from 2024, driven by rapid growth in drug sales, including a new first-line indication ap...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.